Now Available in Five New States

Our Mindbloom Press Roundup: Recent Discussion About Our Mission

Mindbloom’s mission to transform lives to transform the world starts through expanded access to ketamine therapy. Part of expanded access is increased awareness of ketamine therapy as a mental health treatment option, specifically for those working through depression and anxiety.

We’re honored to have been invited to share our mission through recent press features, podcasts, and the stories of our clients. To learn more about Mindbloom’s founding, mission, and the benefits of psychedelic medicine through mental health treatment, check out the recent discussions we’ve been a part of below.

‘I Started Doing At-Home Guided Ketamine Treatments To Help With My Depression During Quarantine’ - Women’s Health

Mindbloom Client Melanie Lowery shares her story with Women's Health

Mindbloom client Melanie Lowery shares her story of living with depression and anxiety for a majority of her life, and how she found ketamine therapy after trying myriad medications that weren’t producing the outcomes she’d hoped for, and produced “horrible” side-effects.

Melanie details what her Mindbloom experience was like, and how —amidst the onset and stress of a global pandemic— she was able to function better after initial ketamine treatment sessions.

“Honestly, I feel like I’m 100 percent in remission from depression. I’ve spent almost my whole life on pharmaceutical drugs, and I'm so glad that's over, at least for now,” Melanie says in the article.

We appreciate Melanie sharing her story, and we encourage you to read other Mindbloom clients’ stories about breakthrough moments in treatment and overcoming anxiety.

Read the full Women’s Health piece here.

Telemedicine, Ketamine Lozenges, and Healing Depression: An Interview with Mindbloom's Dr. Casey Paleos - The Third Wave

Mindbloom Science Director, Dr. Casey Paleos

Mindbloom’s Science Director, Dr. Casey Paleos appears on the Third Wave Podcast to discuss advancements in ketamine therapy, including recent expansion of treatment through telemedicine.

Dr. Paleos shares his personal history as it relates to psychedelics and mental health, impacting his career path. He discusses his involvement in breakthrough clinical research in ketamine treatment for depression and MDMA studies, and his own private practice treating clients through ketamine therapy. He and host Paul Austin also delve into the neuroscience of ketamine, and its effect on neuroplasticity, the default mode network, and how it helps form healthier brain patterns and behavioral changes.

Read the show notes and listen to the podcast through your preferred app here


Mindbloom Founder & CEO Dylan Beynon’s Recent Appearances

Mindbloom Founder and CEO, Dylan Beynon

Dylan Beynon, our Founder and CEO, has been featured on recent podcasts and discussions to talk about Mindbloom’s mission and the future of psychedelic therapy through expanding access to ketamine treatment.

Addicted Mind Podcast - “Mindbloom & Psychedelic Medicine”

Licensed therapist and host Duane Osterlind talks with Dylan about Mindbloom’s inception through the lens of Dylan’s own mental health and psychedelic medicine experiences. The episode touches on ketamine’s role in depression and anxiety treatment, and its inroads into treatment for addiction and substance use disorder.

Addicted Mind show notes and episode here.

The Founder with Kyle Kallaway - “Transforming Lives Through Ketamine Therapy”

Host Kyle Kallaway delves into what led Dylan to found Mindbloom, and how its mission to transform lives to transform the world is helping to expand access to ketamine treatment through telemedicine.

The Founder show notes and episode here.

The Psychedelic News Hour with Dave and Molly - “Mindbloom & Psychedelic Medicine”

Hosts Dr. Molly Maloof, MD and Dr. Rabin, MD PhD hold a panel discussion and Q&A with Dylan about their collective experience in psychedelic-assisted and ketamine therapies, and Mindbloom’s role in the expansion of these breakthrough treatments.

More about The Psychedelic News Hour and its past guests.

Follow “Psychedelic Clubhouse” on the Clubhouse app.

Below the Line with James Beshara - “The Innovative Future of Psychedelics”

Host James Beshara talks with Dylan about how his first-hand experience with familial mental illness was a catalyst in his drive for success and foundation of Mindbloom. They also discuss how the perception of psychedelics is beginning to change, both in general and as a legitimate means of therapeutic intervention.

More about the Below the Line Podcast here.

Follow Mindbloom’s Recent Press and Developments in Psychedelic Medicine 

Mindbloom’s role in breakthrough mental health treatments through psychedelic medicine means we’re featured often in press and discussions.

Our Press page includes recent press and press releases around Mindbloom’s mission, and news and developments around psychedelic medicine and its research.

Considering psychedelic therapy? See if you’re a candidate for this breakthrough depression and anxiety treatment by completing our initial survey.

Explore Mindbloom Treatment

Mindbloom has helped thousands of clients reach new levels of wellbeing. Find out if it's a right fit for you.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Take the Assessment
Take the Assessment
Disclaimer

Sources

This article is for informational purposes only and is not intended to be a substitute for professional medical advice. Always talk to your doctor about the risks and benefits of any treatment. If you are in a life-threatening situation, call the National Suicide Prevention Line at +1 (800) 273-8255, call 911, or go to the nearest emergency room.

Important FDA Safety Information

Ketamine is not FDA-approved for the treatment of depression or anxiety. Learn more about off-label uses here.

Side effects of ketamine treatment may include: altered sense of time, anxiety, blurred vision, diminished ability to see/hear/feel, dry mouth, elevated blood pressure or heart rate, elevated intraocular or intracranial pressure, excitability, loss of appetite, mental confusion, nausea/vomiting, nystagmus (rapid eye movements), restlessness, slurred speech, synesthesia (a mingling of the senses).

Do not proceed with ketamine treatment if any of the following apply to you:

  • Allergic to ketamine
  • Symptoms of psychosis or mania
  • Uncontrolled high blood pressure
  • CHF or other serious heart problem
  • Severe breathing problem
  • History of elevated intraocular or intracranial pressure
  • History of hyperthyroidism
  • Other serious medical illness
  • Pregnant, nursing, or trying to become pregnant

Ketamine has been reported to produce issues including, but not limited to, those listed below. However, lasting adverse side-effects are rare when medical protocols are carefully followed.

While ketamine has not been shown to be physically addictive, it has been shown to cause moderate psychological dependency in some recreational users.

  • In rare cases, frequent, heavy users have reported increased frequency of urination, urinary incontinence, pain urinating, passing blood in the urine, or reduced bladder size
  • Ketamine may worsen problems in people with schizophrenia, severe personality disorders, or other serious mental disorders.
  • Users with a personal or family history of psychosis should be cautious using any psychoactive substance, including ketamine, and discuss potential risks with your MindBloom clinician before proceeding with treatment.
  • The dissociative effects of ketamine may increase patient vulnerability and the risk of accidents.

To promote positive outcomes and ensure safety, follow these ketamine treatment guidelines:

  • Do not operate a vehicle (e.g., car, motorcycle, bicycle) or heavy machinery following treatment until you’ve had a full night of sleep
  • Refrain from taking benzodiazepines or stimulants for 24 hours prior to treatment
  • Continue to take antihypertensive medication as prescribed
  • Avoid hangovers or alcohol intake
  • Refrain from consuming solid foods within 3 hours prior to treatment and liquids within 1 hour prior to treatment
  • Ketamine treatment should never be conducted without a monitor present to ensure your safety
Blog Post -
Our Mindbloom Press Roundup: Recent Discussion About Our Mission